Hematology

Latest News
November 19th 2024

OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM

November 15th 2024

Elevating Myeloma Care Amidst Complex Treatment Choices

November 15th 2024

NUP98 Rearrangements Linked to Poor Outcomes in AML

November 7th 2024

Tacrolimus Linked to Lower Acute GVHD Risk

November 2nd 2024

Patients With MDS Disagree With Physicians About Symptom Frequency

Video Interviews
View All
October 24th 2024

MRD: A Game Changer in Multiple Myeloma

August 24th 2024

New CAR T Trial in MM Aims for Triple Receptor Targeting

July 24th 2024

Financial Considerations Influencing Treatment Strategies in PNH Treatment Pathway

July 24th 2024

Ensuring PNH Treatment Access and Adherence to Therapies

July 23rd 2024

Exploring the Efficacy and Safety of Ibrutinib and Venetoclax in CLL

July 7th 2024

Game-Changing Strategies for Early-Relapsed Myeloma

August 31st 2021

The Future of Acquired TTP

August 26th 2021

Treatment Considerations for Caplacizumab

August 24th 2021

Using Caplacizumab to Treat Acquired TTP

August 19th 2021

Treatment Options for Acquired TTP

Podcasts
View All
July 16th 2024

Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH

September 15th 2018

Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News

May 5th 2018

Podcast: This Week in Managed Care—Insurance Coverage Gains Reverse and Other Health News

March 10th 2018

Podcast: This Week in Managed Care—Verma on Health Data and Other Health News

December 16th 2017

Podcast: This Week in Managed Care—CAR T Treatments and Other Health News

December 14th 2017

Five Years of Reducing Overuse of Medical Services With Choosing Wisely

More News

New therapies for AML and other blood cancers may be informed by the overexpression of 3 proteins | image credit: jovannig - stock.adobe.com
November 2nd 2024

New Work Highlights Proteins as Potential Novel AML Therapeutic Targets

Gayle Turim Dickstein
Three proteins—THRAP3, STMN1, and GNA13—are overrepresented in blood cancers like acute myeloid leukemia (AML) and could prove to be novel targets for future therapies.
Respiratory tract infections may occur in patients with CLL taking BTK inhibitors | image credit: Worldillustrator - stock.adobe.com
November 2nd 2024

Review Emphasizes Potential Infection Risks With BTK Inhibitors

Gayle Turim Dickstein
Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Ibrutinib molecule | image credit: molekuul.be - stock.adobe.com
October 23rd 2024

Understanding Ibrutinib Relapse in CLL: Immune Profiles of Responders vs Relapsing Patients

Kimberly Rath, PharmD
A new study identifies potential immune profile differences in patients with chronic lymphocytic leukemia (CLL) that may lead to resistance after ibrutinib therapy.
Blood smear AML | image credit: Chansom Pantip - stock.adobe.com
October 20th 2024

FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML

AJMC Contributor
The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.
Myeloid malignancy concept, blood cells floating | image credit: Eleni - stock.adobe.com
October 18th 2024

Phase 1b/2 Study Supports Use of Telaglenastat and Azacytidine in Advanced MDS

Kimberly Rath, PharmD
A recent study evaluates the dosing, safety, and efficacy of telaglenastat and azacytidine to treat advanced myelodysplastic syndromes (MDS), with promising results.
Lipopolymer-Delivered RNA Interference Shows Promise Against FLT3-Mutated AML | image credit: Matthieu - stock.adobe.com
October 16th 2024

Lipopolymer-Delivered RNA Interference Shows Promise Against FLT3-Mutated AML

Jared Kaltwasser
Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients with acute myeloid leukemia (AML) with internal tandem duplication in the fms-like tyrosine kinase 3 (FLT3) gene.
Acalabrutinib demonstrates superior safety over ibrutinib in the treatment of CLL/SLL | image credit: sovova - stock.adobe.com
October 9th 2024

Real-World Data: Acalabrutinib Safety Profile Superior in CLL/SLL

Jared Kaltwasser
A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib shows the former had lower rates of adverse events in a real-world setting.
AML cells | image credit: TheWaterMeloonProjec - stock.adobe.com
October 3rd 2024

New Study Further Illuminates PARP1 Expression in ALL, AML, CML With BCR::ABL1 p190+

Kimberly Rath, PharmD
Researchers investigate the expression of PARP1 in leukemias with BCR::ABL1 p190+ translocation, finding differential expression in ALL, AML, and CML but no significant correlation with clinical parameters.
Surbhi Sidana, MD, MBBS, Stanford University
October 2nd 2024

Isatuximab Approval Highlights Role of Anti-CD38 Antibody in Myeloma Care

Maggie L. Shaw
On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients who have multiple myeloma and are ineligible for transplant.
Switching patients with hemophilia B to gene therapy may compound immense health care savings in the long term | image credit: ejgrubbs - stock.adobe.com
September 25th 2024

Gene Therapy for Hemophilia B Could Lower Health Plans’ Budget Over Time

Jared Kaltwasser
Health plans would see savings faster if they switched to etranacogene dezaparvovec sooner, the investigators found.
Understanding genetic alterations in CLL could improve personalized medicine strategies | image credit: Shuo - stock.adobe.com
September 24th 2024

Exploring the Impact of TP53 Alterations on miR-34a and NOTCH1 in CLL

Kimberly Rath, PharmD
New study provides insights into the relationship between TP53, miR-34a, and NOTCH1 in CLL cells.
Hemoglobin is responsible for transporting oxygen throughout the body, which is imperative for a multitude of functions | image credit: Justlight - stock.adobe.com
September 21st 2024

Low Hemoglobin, IDH2 Mutation Indicative of Poor Survival in MDS

Nameera Temkar, MD
Results from a retrospective study compared and explored biomarkers associated with outcomes in myelodysplastic syndrome (MDS) with plasma cell neoplasms.
NHL cells | image credit: sovova - stock.adobe.com
September 21st 2024

Lenalidomide-Obinutuzumab Combo Yields Promising Results in Relapsed NHL

Kimberly Rath, PharmD
A new study demonstrates that the combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) is effective and well-tolerated in treating relapsed indolent non-Hodgkin lymphoma (NHL).
Sickle cell anemia affects an estimated 100,000 people in the US | image credit: Studios - stock.adobe.com
September 20th 2024

Urinary Angiotensinogen Predicts Persistent Albuminuria in Sickle Cell Anemia

Karen Jacobson-Sive
Patients with sickle cell anemia (SCA) and persistent albuminuria (PA) exhibited significantly higher levels of urinary angiotensinogen (AGT).
Genetic variation and sex-specific differences may be related to pain in SCD | image credit: Lila Patel - stock.adobe.com
September 18th 2024

Pain in SCD: Are Genetic Variations Responsible?

Nameera Temkar, MD
Genetic variability and sex-specific differences may play a role in sickle cell disease (SCD)-related pain; however, more research is needed.
Risk stratification in AML could benefit from mutational scoring | image credit: faraktinov - stock.adobe.com
September 17th 2024

Mutational Score May Improve Risk Stratification of Certain Patients With AML

AJMC Contributor
The researchers suggest certain refinements to the 2022 European LeukemiaNet classification model for patients aged 60 years or older receiving lower intensity treatment (LIT), including the adoption of a mutation score that accounts for certain gene mutations.
Tablet with blue screen and multiple myeloma written in white with a stethoscope on top | Image credit: ibreakstock-stock.adobe.com
September 14th 2024

CAR T Reduces All-Cause Mortality Greater Than a Bispecific Antibody in MM

Laura Joszt, MA
Using real-world data, researchers compared 2 chimeric antigen receptor (CAR) T-cell therapies with a bispecific antibody, teclistamab, in multiple myeloma (MM).
Celiac disease and the body | Image Credit: reineg-stock.adobe.com
September 13th 2024

Celiac Disease Associated With Varying Risks for Cancers

Karen Jacobson-Sive
Celiac disease presents a higher risk for developing malignant neoplasms, including small intestine, lymphoma, and skin cancers, but presents a lower risk for respiratory malignancies.
Patients with SCD have reportedly felt stigmatized due to their race, pain, and more | image credit: Andrey Popov - stock.adobe.com
September 11th 2024

Study: Patients With SCD Report Discrimination Based on Race, Pain, and Other Factors

Jared Kaltwasser
A new report based on patient focus groups suggests many clinicians can do more to help patients with sickle cell disease (SCD) feel heard and understood.
Recombinant Hirudin shows promise in the treament of DLBCL | image credit: David A Litman - stock.adobe.com
September 5th 2024

Recombinant Hirudin May Help Treat Diffuse Large B-Cell Lymphoma 

Karen Jacobson-Sive
Recombinant Hirudin (rH) inhibited the polarization of M2-type macrophages and protease-activated receptor-1 (PAR-1) in diffuse large B-cell lymphoma (DLBCL).
red blood cells model CLL | image credit: digitalpochi - stock.adobe.com
September 4th 2024

B-Cell Activating Factor Levels May Predict Reduced Risk of CLL, Study Finds

Kimberly Rath, PharmD
A recent study has found that higher serum levels of B-cell activating factor and anti-CCP3 are associated with a reduced risk of developing chronic lymphocytic leukemia (CLL), suggesting potential biomarkers for assessing CLL risk.
Telomeres act as protective caps on the ends of chromosomes | image credit: Anastasiia - stock.adobe.com
September 3rd 2024

RIOK2 Regulates Telomerase Subunits to Prevent Telomere Shortening

Gwen Mergian
New research linking telomere shortening to myelodysplastic syndromes (MDS) offers substantial therapeutic implications for affected patients and MDS research.
Despite treatment, some patients with PNH still experience anemia | image credit: ImageFlow - stock.adobe.com
August 28th 2024

Pegcetacoplan May Reduce Fatigue in PNH Accompanied by Anemia

Kyle Munz
Findings from a post hoc analysis of 3 clinical trials support the switching to or initiation of pegcetacoplan to manage fatigue for patients with paroxysmal nocturnal hemoglobinuria (PNH) that is accompanied by mild to moderate anemia.
Immunology word cloud | image credit: ibreakstock - stock.adobe.com
August 27th 2024

Researchers Identify Potential IO Targets in AML Through Surfaceome Analysis

AJMC Contributor
By analyzing the surface proteome of a wide-ranging sample of acute myeloid leukemia (AML) specimens, researchers identified potential antigens and primitive cell markers representative of AML supgroups.
Cancerous cells | image credit: Dr_Microbe - stock.adobe.com
August 26th 2024

Multiplex Spatial Analysis Highlights Mechanisms of Refractory cHL

Jared Kaltwasser
Improvements in multiplex immunofluorescence and spatial analysis have enabled a better understanding of the ways classical Hodgkin lymphoma evades the immune system.
Skin cancer is a dangerous morbidity risk in patients with CLL | image credit: Ocskay Mark - stock.adobe.com
August 26th 2024

Study Implicates AXL in Skin Cancer Development in CLL

Jared Kaltwasser
The authors said their findings also suggest AXL inhibition might be an important therapeutic strategy.
stem cells | Image Credit: jarun011-stock.adobe.com
August 20th 2024

Second ASCT Extends Survival in Relapsed Multiple Myeloma

Maggie L. Shaw
To continue the response they experienced with a first autologous stem‐cell transplant (ASCT) for their multiple myeloma, patients in this analysis received a second ASCT, with French investigators evaluating their outcomes.
CLL cells | image credit: Arif Biswas - stock.adobe.com
August 19th 2024

Novel Targeted Therapies Show Superiority in Relapsed/Refractory CLL

Nameera Temkar, MD
A meta-analysis demonstrated the superiority of Bruton tyrosine kinase inhibitors (BKTi) in the overall survival of patients with chronic lymphocytic leukemia compared with other therapies.
Quality of life in patients with hemophilia A or B benefits from the use of concizumab | image credit: Patrick Daxenbichler - stock.adobe.com
August 18th 2024

Patient-Reported Outcomes Favor Concizumab Prophylaxis in Hemophilia A or B

Connor Iapoce
Analysis of the phase 3 explorer7 (NCT04083781) study indicates a preference for concizumab prophylaxis over no prophylaxis in patients with hemophilia A or B with inhibitors.
AML cells | image credit: LASZLO - stock.adobe.com
August 17th 2024

AML Treatment Has Shifted Toward More Personalized Approach

AJMC Contributor
Recent years have brought a more targeted approach to treating acute myeloid leukemia (AML) based on accumulating knowledge about the genetic makeup of the heterogenous disease.
12345678
...
23>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo